New Ichthyosporaceae microorganisms and uses thereof
Through the Epidermidibacterium strain and culture medium of the novel Aphrosporidae family, the problems of skin barrier function damage and inflammation-related diseases have been solved, significantly improved the skin environment and barrier function, enhanced the skin's moisturization and anti-inflammatory ability, and used in a variety of ways. Treatment of skin and inflammation-related conditions.
Patent Information
- Application Number
- CN202210228306.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-06-16
- Filing Date
- 2017-06-27
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2037-06-27
AI Technical Summary
The prior art is difficult to effectively improve the skin environment, especially the loss of moisture and wrinkle problems caused by damage to skin barrier function, and the treatment effect on skin-related and inflammation-related diseases is limited.
A novel strain of the Epidermidibacterium genus Epidermidibacterium has been discovered and identified, with specific bacteriological and physiological characteristics, capable of inducing changes in the skin microbial community, and is used to prevent, improve or treat the skin through its culture fluid or composition. Related and inflammation-related conditions.
This strain or its culture solution can increase the expression of cylindrical protein, tight junction protein, αSMase, CerS3 and HAS in skin cells, reduce the expression of inflammation-related factors and pruritus-related factors, significantly improve skin barrier function, and enhance skin moisturization Ability and anti-inflammatory activity, effective in the treatment of a variety of skin and inflammation-related conditions.
Smart Images

Figure CN114767613B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application is a divisional application of the Chinese patent application with application number 201780003181.5 filed on June 27, 2017. Technical Field
[0003] The present invention relates to novel Sporichthyaceae microorganisms and uses thereof. Background Art
[0004] The skin ecosystem provides a variety of habitats for microorganisms, and various microorganisms occupy the skin ecosystem. These microorganisms are known to have a symbiotic relationship with their human host and have many positive effects on the host. The skin forms various habitats such as invaginations, specific niches, etc., which help various microorganisms grow. The main role of the skin is to form a physical barrier and provide protection from potential threats from the external environment and toxic substances. The skin is an interface with the external environment and is colonized by various microorganisms (fungi, bacteria, viruses and small larvae). Microorganisms that adapt to the niches in which microorganisms live are selected based on the selection of physical and chemical functions. In general, the skin is cool, acidic, and remains dry. Structurally, the epidermis plays the role of forming a physical barrier and resisting the penetration of microorganisms and toxins while retaining moisture. The outermost layer of the epidermis consists of the stratum corneum. The epidermis forms the so-called "brick and mortar" structure, the skin tissue undergoes continuous self-renewal, and in the final stage of differentiation, scales are continuously shed from the skin surface.
[0005] Probiotics are collectively referred to as microorganisms that are beneficial to the human body and are microorganisms that are beneficial to our body. Most of the probiotics known to date are lactic acid bacteria. Probiotics are reported to show efficacy through various beneficial effects on the human body, but there are few studies on the correlation between skin flora and skin.
[0006] The skin barrier is composed of dead keratinocytes and intercellular lipids. The skin barrier is a protective layer of the skin that protects the skin from external stimuli and prevents the evaporation of water through the skin, and plays a key role in maintaining skin health. That is, the skin barrier prevents excessive loss of water from the body and prevents the entry of harmful substances such as chemicals or microorganisms. The keratinocyte envelope that constitutes the surface of dead keratinocytes plays an important role in the stability of intercellular lipids. Keratinocytes differentiate to form a skin barrier through cornification. The function of the skin barrier may be damaged with aging or by external factors, and damage to the skin barrier may lead to skin moisture loss and wrinkles.
[0007] Therefore, the inventors examined the changes occurring in the skin according to the changes in the skin flora, and furthermore, studied whether the skin environment can be potentially improved by inducing changes in the skin flora. As a result, it was found that a novel Ichthyosporaceae strain was isolated and identified from the skin of healthy adults, and it was found that the strain or its culture can induce changes in the skin microbial community, thereby improving the skin environment, and can be used for skin-related diseases, thereby completing the present invention. Summary of the invention
[0008] Technical issues
[0009] In one aspect, a novel Epidermidibacterium strain belonging to the family Ichthyosporaceae is provided.
[0010] Another aspect provides a culture solution of the strain.
[0011] Another aspect provides a composition comprising an Epidermidibacterium strain or a culture fluid thereof.
[0012] Another aspect provides a composition for preventing, ameliorating or treating a condition in a subject, comprising an Epidermidibacterium strain or a culture fluid thereof.
[0013] Another aspect provides use of an Epidermidibacterium strain or a culture solution thereof in preparing a composition.
[0014] Another aspect provides use of an Epidermidibacterium strain or a culture solution thereof in preparing a composition for preventing, ameliorating or treating a disease in a subject.
[0015] Another aspect provides a method for preventing, ameliorating or treating a condition in a subject, the method comprising administering an Epidermidibacterium strain or a culture fluid thereof to a subject in need thereof.
[0016] Technical Solution
[0017] In one aspect, novel strains of the genus Epidermidibacterium belonging to the family Ichthyosporaceae are provided.
[0018] Epidermidibacterium strains may have one or more of the following mycological characteristics:
[0019] (1) Rod-shaped;
[0020] (2) non-motile;
[0021] (3) Gram-positive;
[0022] (4) Non-spore forming;
[0023] (5) oxidase negative and / or catalase negative;
[0024] (6) MK-9(H4) can be detected therefrom;
[0025] (7) the polar lipid is one or more selected from the group consisting of phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylglycerol (PG), phosphatidylcholine (PC) and three unidentified lipids (UL); and
[0026] (8) The DNA G+C content is 68.9 mol%.
[0027] There were obvious differences between the Epidermidibacterium strain and other strains of different genera in terms of phylogenetic and chemotaxonomic characteristics, so the strain was identified as a new Epidermidibacterium strain.
[0028] The Epidermidibacterium strain may include Epidermidibacterium keratini.
[0029] Epidermidibacterium keratini may have one or more of the following mycologic features:
[0030] (1) The cell length is 0.5 μm to 0.3 μm and the diameter is 0.3 μm to 0.1 μm;
[0031] (2) The colonies are round, convex, and light yellow;
[0032] (3) Growth was observed on R2A (Reasoner's 2A) agar, but no growth was observed on nutrient agar (NA), yeast extract malt extract agar (ISP 2), and trypticase soy agar (TSA);
[0033] (4) On R2A agar, growth was observed at 15°C to 35°C (optimum temperature: 25°C), but no growth was observed at 10°C or 40°C;
[0034] (5) Growth was observed at pH 5.0 to 6.5 and NaCl concentrations up to 10% (optimum pH 6.0, 0% NaCl);
[0035] (6) Reduction of nitrate to nitrite;
[0036] (7) Casein and starch are degraded, but DNA and carboxymethyl cellulose are not degraded;
[0037] (8) The characteristics described in Tables 1 to 3 were observed;
[0038] (9) showing positive assimilation of one or more of the following: N-acetyl-D-glucosamine, N-acetyl-β-D-mannosamine, α-D-glucose, D-mannose, D-fructose, D-galactose, dextrin, D-fucose, inosine, lactamide, maltotriose, D-psicose, D-ribose, α-ketovaleric acid, D-fructose-6-PO4, L-serine, pectin, pyruvate, adenosine, thymidine, 2'-deoxyadenosine, 5'-adenosine monophosphate, p-hydroxyphenylacetic acid, methyl pyruvate, methyl D-lactate, L-lactic acid, citric acid, α-ketoglutaric acid, D-malic acid, L-malic acid, bromosuccinic acid, Tween 40, Tween 80, α-hydroxybutyric acid, β-hydroxy-D,L-butyric acid, α-ketobutyric acid, propionic acid, and acetic acid activity;
[0039] (10) Negative assimilation of one or more of the following: D-maltose, D-cellobiose, gentiobiose, sucrose, D-turanose, stachyose, D-raffinose, α-D-lactose, D-melibiose, β-hydroxy-methyl-D-glucoside, D-salicylic acid, N-acetyl-D-galactosamine, N-acetylneuraminic acid, D-sorbitol, D-mannitol, D-arabitol, inositol, glycerol, D-glucose-6-PO4, D-aspartic acid, D-serine, gelatin, glycyl-L- -Proline, L-Alanine, L-Arginine, L-Aspartic Acid, L-Glutamic Acid, L-Histidine, L-Pyroglutamic Acid, D-Galacturonic Acid, L-Galactone, D-Glucuronic Acid, D-Glucuronic Acid, Glucuronamide, Mucic Acid, Quinic Acid, D-Glucose, γ-Aminobutyric Acid, Formic Acid, α-Cyclodextrin, β-Cyclodextrin, Glycogen, Inulin, Mannan, N-Acetyl-D-Glucosamine, N-Acetyl-β-D-Mannosamine, Amygdalus Indole, L-Arabinose, Arbutin, L-Fucose, D-galactose, D-galacturonic acid, D-gluconic acid, lactulose, D-melezitose, α-methyl-D-galactoside, β-methyl-D-galactoside, 3-methylglucose, α-methyl-D-glucoside, β-methyl-D-glucoside, α-methyl-D-mannoside, palatinose, L-rhamnose, salicin, sedoheptalan, D-tagatose, D-trehalose, turanose, xylitol, D-xylose, acetic acid, γ-hydroxybutyric acid, p-hydroxyphenylacetic acid, D-methyl lactate, D-malic acid , L-malic acid, methyl pyruvate, monomethyl succinate, propionic acid, succinamic acid, N-acetyl-L-glutamate, L-alanineamine, D-alanine, L-alanylglycerol, glycyl-L-glutamate, L-pyroglutamate, putrescine, 2,3-butanediol, uridine, thymidine-5'-monophosphate, uridine-5'-monophosphate, D-fructose-6-phosphate, α-D-glucose-1-phosphate, D-glucose-6-phosphate, and DL-α-glycerophosphate;
[0040] (11) the presence of one or more activities selected from the group consisting of esterase (C4), esterase lipase (C8), leucine aryl amidase, cystine (crystine) aryl amidase, acid phosphatase, and naphthol-AS-BI-phosphohydrolase activity;
[0041] (12) the presence of weak alkaline phosphatase, valine arylamidase, or α-chymotrypsin activity;
[0042] (13) absence of one or more activities selected from the group consisting of lipase (C14), trypsin, α-galactosidase, β-glucuronidase, β-glucosidase, α-glucosidase, N-acetyl-β-glucosaminidase, α-mannosidase, and α-fucosidase activities; and
[0043] (14) The main fatty acids are C17:1ω8c, C16:0, iso-C15:0 or summed feature 3 (C 16:1 ω6c and / or C 16:1 ω7c).
[0044] Epidermidibacterium strains or Epidermidibacterium keratini may have one or more of the following morphological characteristics:
[0045] (1) Rod-shaped;
[0046] (2) non-motor;
[0047] (3) No flagella;
[0048] (4) Gram-positive;
[0049] (5) No spores;
[0050] (6) The length of the cells is 0.5 μm to 0.3 μm and the diameter is 0.3 μm to 0.1 μm; and
[0051] (7) The colonies are round, convex and light yellow.
[0052] Epidermidibacterium strains or Epidermidibacterium keratini may have one or more of the following cultural and physiological characteristics:
[0053] (1) Aerobic;
[0054] (2) Heterotrophy;
[0055] (3) Oxidase negative and / or catalase negative
[0056] (4) Characteristics of Table 1;
[0057] (5) Growth was observed on R2A agar, but not on NA, ISP 2, and TSA;
[0058] (6) On R2A agar, growth was observed at 15°C to 35°C (optimum temperature: 25°C), but no growth was observed at 10°C or 40°C;
[0059] (7) Growth was observed at pH 5.0 to 6.5 and NaCl concentrations up to 10% (optimum pH 6.0, 0% NaCl);
[0060] (8) reduction of nitrate to nitrite; and
[0061] (9) Casein and starch are degraded, but DNA and carboxymethyl cellulose are not degraded.
[0062] Epidermidibacterium strains or Epidermidibacterium keratini may have one or more of the following biochemical characteristics:
[0063] (1) Tetrahydromethyl menaquinone (MK-9(H4)) with 9 units is the only isoprenoid quinone detected;
[0064] (2) the major polar lipid is one or more selected from the group consisting of phosphatidylethanolamine (PE), phosphatidylinositol (PI), three unidentified phospholipids (UPL), phosphatidylglycerol (PG), phosphatidylcholine (PC), two unidentified amino lipids (AL) and three UL;
[0065] (3) DNA G+C content is 68.9 mol%; and
[0066] (4) Fatty acid composition of Table 2.
[0067] Epidermidibacterium keratini may include a 16S rRNA gene having the base sequence of SEQ ID NO:1.
[0068] Epidermidibacterium keratini may be deposited under accession number KCCM 11843P.
[0069] In another aspect, a culture medium of Epidermidibacterium genus or Epidermidibacterium keratini is provided.
[0070] As used herein, the term "culture broth" refers to a culture broth obtained by culturing a strain, a concentrate thereof, or a lyophilized product thereof, or a culture supernatant obtained by removing the strain from the culture broth, a concentrate thereof, or a lyophilized product thereof, and "culture supernatant", "conditioned culture broth" and "conditioned medium" can be used interchangeably therewith.
[0071] The culture solution can be obtained by culturing Epidermidibacterium genus or Epidermidibacterium keratini in R2A medium at any temperature higher than 10°C or lower than 40°C for a predetermined period of time (eg, 4 to 50 hours).
[0072] In a specific embodiment, the culture supernatant of the strain can be obtained by removing the strain from the culture solution of the strain by centrifugation or filtration.
[0073] In another specific embodiment, the concentrate can be obtained by concentrating the strain culture solution itself or the supernatant, and the supernatant is obtained by centrifuging the culture solution or filtering the culture solution using a filter.
[0074] Those skilled in the art can appropriately select or modify the culture medium and culture conditions for culturing Epidermidibacterium spp.
[0075] Another aspect provides use of Epidermidibacterium spp. or a culture fluid thereof in preparing a composition, and in particular provides a composition comprising Epidermidibacterium spp. or a culture fluid thereof.
[0076] Epidermidibacterium spp. or culture medium thereof are as described above.
[0077] In a specific embodiment, the Epidermidibacterium strain or its culture solution can increase the expression of filaggrin, claudin, αSMase, CerS3, transglutaminase-1 and HAS in skin cells, and reduce the expression of inflammation-related factors and pruritus-related factors. Therefore, the Epidermidibacterium strain can be effectively used for skin-related diseases or inflammation-related diseases.
[0078] Examples of skin-related conditions may include skin aging, wounds, dermatitis, atopic dermatitis, pruritus, eczematous skin diseases, dry eczema, erythema, urticaria, psoriasis, drug eruptions, papulosquamous diseases, insect and parasite-mediated diseases, superficial dermatophytes, bacterial infectious diseases, viral diseases, sexually transmitted diseases, autoimmune bullous diseases, connective tissue diseases, dyschromatosis, xeroderma pigmentosum, acne, etc.
[0079] Inflammation-related conditions may include dermatitis, allergies, atopy, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, frozen shoulder, tendinitis, tenosynovitis, peritendinitis, myositis, hepatitis, cystitis, nephritis, Sjögren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases.
[0080] Relative to the total weight of the composition, the composition can contain 0.001% to 80% by weight of the strain or its culture fluid, such as 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight, 0.01% to 20% by weight, 0.01% to 10% by weight, 0.01% to 5% by weight, 0.05% to 60% by weight, 0.05% to 40% by weight, 0.05% to 30% by weight, 0.05% to 20% by weight, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight, 0.1% to 10% by weight, or 0.1% to 5% by weight of the strain or its culture fluid.
[0081] Hereinafter, the use of the Epidermidibacterium strain according to the composition will be described in detail.
[0082] The composition may be a cosmetic composition.
[0083] In specific embodiments, the cosmetic composition can enhance the skin barrier; prevent, improve, or inhibit aging; prevent or improve pruritus; and prevent or improve inflammation.
[0084] When used herein, the term "skin aging" refers to the tangible and intangible changes that occur on the skin as age increases, such as reduced epidermal thickness, reduced number of skin cells or blood vessels, reduced ability to repair DNA damage, reduced cell renewal, delayed wound healing, reduced skin barrier function, reduced water retention in the epidermis, reduced sweat and sebum secretion, reduced vitamin D production, reduced defense against physical damage, reduced chemical removal ability, reduced immune reactivity, reduced sensory function, reduced body temperature control, etc. Epidermidibacterium strains or their culture fluids can be used to improve skin aging caused by exogenous or endogenous factors. Exogenous factors refer to many external factors, such as ultraviolet rays (light), while endogenous factors are also called timing factors, which refer to factors that occur mainly over time. That is, skin aging particularly includes not only early aging caused by external stimuli (such as UV, air pollution, cigarette smoke, chemicals, etc.), but also natural aging that occurs due to reduced skin cell proliferation as age increases. Skin aging is a concept that includes all of the following: wrinkles, loss of elasticity, sagging skin, dryness, etc. In addition, wrinkles include wrinkles caused by changes in the components that constitute the skin tissue caused by the stimulation of internal / external factors.
[0085] Therefore, since the composition can have the above-mentioned effects, it can be used for skin improvement such as skin moisturizing, prevention of skin aging, enhancement of skin barrier, skin wound healing or skin inflammation inhibition.
[0086] The cosmetic composition may have, for example, a softening lotion, a nourishing lotion, a massage cream, a nourishing cream, an essence, a mask, a gel, an ampoule, a skin adhesive type cosmetic preparation.
[0087] The cosmetic composition may further include components commonly used in cosmetic compositions, such as common additives and carriers, such as stabilizers, solubilizers, vitamins, pigments and fragrances, in addition to the composition as an active ingredient.
[0088] Furthermore, the composition may be a composition for external use on the skin.
[0089] In the present disclosure, the skin external preparation can be a cream, a gel, an ointment, a skin emulsifier, a skin suspension, a transdermal patch, a medicated bandage, an emulsion or a combination thereof. As required, the above-mentioned skin external preparation can be appropriately mixed with the components used in the skin external preparation of, for example, common cosmetics or medicines, such as aqueous components, oily components, powder components, alcohols, wetting agents, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, spices, pigments, various skin nutrients or a combination thereof. The above-mentioned external skin preparations can be appropriately mixed with the following substances: chelating agents (e.g., disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid), caffeine, tannic acid, verapamil, licorice extract, glabridin, hot water extract of Calin fruit, various herbs, tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or their salts and the like, vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside, arbutin, kojic acid, sugars such as glucose, fructose, trehalose and the like.
[0090] In another specific embodiment, the composition can be a pharmaceutical composition.
[0091] The pharmaceutical composition may also include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose or mannitol, and the lubricant may be magnesium stearate, talc or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium carboxymethyl starch, anhydrous calcium dihydrogen phosphate or a combination thereof. The binder may be polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc or a combination thereof.
[0092] The pharmaceutical composition can be formulated into a preparation for oral or parenteral administration. The preparation for oral administration can be a granule, a powder, a liquid, a tablet, a capsule, a dry syrup or a combination thereof. The preparation for parenteral administration can be an injection.
[0093] The composition may be a health functional food composition.
[0094] In the health functional food composition, according to the general method, the Epidermidibacterium strain or its culture solution can be used alone or in combination with other foods or food ingredients. The mixing ratio of the active ingredient can be determined according to the purpose of use (prevention, health or treatment). Generally, in order to produce food or beverages, the composition of the present disclosure can be added in an amount of 15 parts by weight or less relative to the raw material. The type of health functional food is not particularly limited. In various health functional foods, the beverage composition can contain various flavorings or natural carbohydrates as additional ingredients, like ordinary beverages. Natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As a sweetener, a natural sweetener such as thaumatin and stevia extract can be used, or a synthetic sweetener such as saccharin and aspartame can be used. The health food composition may include nutrients, vitamins, electrolytes, flavoring agents, colorants, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin agents, alcohols, carbonating agents used in carbonated beverages, or a combination thereof. The health functional food composition may also include natural fruit juices, fruit juice drinks, pulp for preparing vegetable beverages, or a combination thereof.
[0095] In addition, another aspect provides a method for preventing, improving or treating a condition in a subject, the method comprising treating or administering an effective amount of an Epidermidibacterium strain, a culture solution thereof or a composition comprising the same to a subject in need thereof.
[0096] The condition of the subject may be a skin-related condition or an inflammation-related condition. The composition is the same as described above. The subject may be a mammal, such as a human, a cow, a horse, a pig, a dog, a sheep, a goat or a cat.
[0097] Beneficial Effects
[0098] According to one aspect, the novel Ichthyosporaceae strain has systematic taxonomic characteristics and chemical taxonomic characteristics that are different from other strains of different families or different genera of the same family. Therefore, the novel Ichthyosporaceae strain or its culture solution can be effectively used to prevent, improve or treat skin-related diseases or inflammation-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0099] Figure 1 is a graph showing the systematic classification results of EPI-7;
[0100] Figure 2 is a diagram showing the morphological characteristics of EPI-7;
[0101] Figure 3 is a graph showing changes in skin flora according to EPI-7 treatment;
[0102] Figure 4 is a graph showing changes in skin flora according to EPI-7 treatment;
[0103] Figure 5 is a graph showing a comparison of the effects of EPI-7 on filaggrin expression in human keratinocytes and a positive control group;
[0104] Figure 6 is a graph showing a comparison of the effects of EPI-7 on the expression of claudin 4 in human keratinocytes and a positive control group;
[0105] Figure 7 is a graph showing the effects of different doses of EPI-7 on the expression of claudin 4 in human keratinocytes;
[0106] Figure 8 is a graph showing a comparison of the effects of EPI-7 on CerS3 expression in human keratinocytes and a positive control group;
[0107] Fig. 9 is a graph showing the effects of different doses of EPI-7 on CerS3 expression in human keratinocytes;
[0108] Fig.10 is a graph showing a comparison of the effects of EPI-7 on αSMase expression in human keratinocytes and a positive control group;
[0109] Fig.11 is a graph showing the effects of different doses of EPI-7 on αSMase expression in human keratinocytes;
[0110] Fig.12 is a graph showing a comparison of the effects of EPI-7 on HAS expression in human keratinocytes and a positive control group;
[0111] Fig.13 is a graph showing the effects of different doses of EPI-7 on HAS expression in human keratinocytes;
[0112] Fig.14 is a graph showing a comparison of the effects of EPI-7 on transglutaminase 1 expression in human keratinocytes and a positive control group;
[0113] Fig.15 is a graph showing the effects of different doses of EPI-7 on the expression of claudin 1 in human keratinocytes;
[0114] Fig.16 is a graph showing the effects of different doses of EPI-7 on the expression of aquaporin 3 in human keratinocytes;
[0115] Fig.17 A graph showing the effect of EPI-7 on inflammatory factors;
[0116] Fig.18 is a graph showing the effects of different doses of EPI-7 on TSLP expression in human keratinocytes;
[0117] Fig.19 is a graph showing the effects of different doses of EPI-7 on TARC expression in human keratinocytes; and
[0118] Fig. 20 is a graph showing the effect of EPI-7 on cell viability. DETAILED DESCRIPTION
[0119] Hereinafter, the present disclosure will be described in more detail with reference to Examples. However, these Examples are for illustrative purposes only, and the scope of the present disclosure is not intended to be limited by these Examples.
[0120] Example 1. Isolation of strains
[0121] The samples (human epidermal keratinocytes) obtained by washing the skin of healthy women with sterile distilled water were inoculated in Reasoner's 2A (R2A) medium (Becton Dickinson, Cockeysville, MD). After inoculation, the samples were cultured in an incubator at 28°C for 48 hours, 100 colonies were isolated and cultured, and then cultured in an incubator at 28°C for another 48 hours. The colonies that completed the culture were identified by 16s rRNA gene sequencing. The primers (sequence numbers 2 and 3) used at this time were designed to react and amplify only in bacteria. PCR amplification was performed for 30 cycles, with 1 minute at 95°C, 1 minute at 55°C, and 1 minute and 30 seconds at 75°C in each cycle, and finally 8 minutes at 72°C. The product was stored at 4°C. The DNA sequence of the species isolated and cultured after the PCR reaction was determined using ABI-3730XL (ABI, USA). The base sequence of the 16S rRNA region determined in the colony of the isolated and cultured microorganism was compared with the base sequences of other strains registered in the BLAST program provided by the homepage of the National Center for Biotechnology Information (NCBI). Only novel species with 97% or less homology were selected and used, and novel microorganisms with 94% or less homology were selected among them (hereinafter referred to as "EPI-7"). EPI-7 has a 16s rRNA sequence with sequence number 1 (complementary DNA).
[0122] Example 2. Taxonomic and mycological characteristics of novel microorganisms
[0123] 2.1. Taxonomic characteristics
[0124] 16S rRNA homology analysis was calculated using the ExTaxon-e server (Yoon SH et al., (2017)). Sequence data were aligned using the software package BioEdit (Hall TA (1999)), and phylogenetic analysis was performed using MEGA version 5.05 (Tamura, K et al., (2011)). The phylogenetic tree was constructed using neighbor-joining analysis (Sitou and Nei (1987)), maximum likelihood estimation, and maximum parsimony algorithms, and the stability of the phylogenetic tree was assessed by bootstrap analysis (1000 replicates) (Felsenstein 1985).
[0125] The results showed that EPI-7 had 93.4%, 93.2%, 93.0%, 93.0% and 92.9% homology with Modestobacter lapidis MON 3.1, Sporichthya polymorpha DSM 43042, Modestobacter marinus 42H12-1, Modestobacter roseus KLBMP1279 and Modestobacter versicolor CP153-2, respectively. Figure 1 As shown in , the results of the constructed phylogenetic tree showed that EPI-7 was a new microorganism belonging to the Ichthyosporaceae family, which had not been reported before.
[0126] 2.2. Mycological characteristics
[0127] Morphological characteristics
[0128] The morphological characteristics of EPI-7 were analyzed as follows.
[0129] First, after culturing the cells in R2A medium at 25°C for 5 days, the cell morphology of EPI-7 was observed under an Olympus microscope (GX71) at a magnification of 1000 times.
[0130] Gliding motility was studied by applying the hanging drop technique to fresh EPI-7 cells in R2A medium.
[0131] For scanning electron microscopy (SEM), the samples were pretreated as follows. EPI-7 was inoculated on R2A (Becton Dickinson, Cockeysville, MD) solid culture medium and cultured for 3 days, and then the membrane filter was attached to the formed colonies. The membrane filter with the colony attached was separated and fixed in a 2.5% glutaraldehyde solution for 2 hours, and then washed twice with PBS for 5 minutes. Thereafter, the membrane filter was treated with a 2% osmium tetroxide solution for 1 hour and dehydrated with 40%, 50%, 60%, 70%, 80%, 90% and 100% ethanol. The dehydrated sample was treated with isoamyl acetate to remove ethanol therefrom. The pretreated sample was dried naturally and sputtered with gold by using a sputter coater (SC502, Polaron). Afterwards, the sample was photographed using SEM (Hitachi S4300N, Hitachi, Japan) at 10000 times and 100000 times, and the results are shown in Figure 2 middle.
[0132] In order to distinguish Gram-positive and Gram-negative bacteria, the experiment was performed as follows. Specifically, a colony of EPI-7 well cultured on R2A solid medium was collected and fixed on a slide. The slide was completely dried, then stained with crystal violet for 1 to 2 minutes, washed with running water and dried again. The dried slide was stained with iodine-potassium iodide for 1 minute. Thereafter, the slide was decolorized with ethanol, washed with running water, and then dried. In order to determine whether the sample is Gram-positive or negative, a red staining dye such as safranin was used for secondary staining for 1 to 3 minutes, and the slide was washed with water and observed under a microscope (Olympus microscope, 12GX71).
[0133] The results showed that EPI-7 has the following morphological characteristics:
[0134] (1) Rod-shaped;
[0135] (2) non-motor;
[0136] (3) No flagella;
[0137] (4) Gram-positive;
[0138] (5) No spores;
[0139] (6) The length of the cells is 0.5 μm to 0.3 μm and the diameter is 0.3 μm to 0.1 μm; and
[0140] (7) The colonies are round, convex and light yellow.
[0141] 2.2.2. Culture and physiological characteristics
[0142] To investigate the culture conditions of EPI-7, the optimal culture temperature was determined by setting the optimal growth temperature at 5°C to 40°C (5°C intervals), and by adding 0% (w / v) to 15% (w / v) (0.5% intervals) of NaCl to the culture medium, followed by culturing for 5 days at 25°C. The pH value was determined by using the following buffer systems: sodium acetate / acetic acid (pH <6), Tris / HCl (pH 6 to pH 9), and glycine / sodium hydroxide (pH>9).
[0143] In addition, catalase activity was determined by analyzing foam production in 3% (v / v) H2O2, and oxidase activity was determined by using 1% (v / v) tetramethylphenylenediamine.
[0144] In addition, to test the growth medium, nutrient agar (NA), yeast extract malt extract agar (ISP2), and trypticase soy agar medium (BD, USA) were used for culturing at 25°C for 5 days.
[0145] In addition, BioLog GP2, BioLog Gen III, API 20NE and API ZYM (Merieux, France) were used to study the material utilization of EPI-7. The method of use was carried out according to the manual provided by the manufacturer. When a positive reaction occurs, a purple color is produced. After visual inspection, the degree of growth is accurately determined using a microplate spectrophotometer. The API ZYM test was analyzed after 4 hours of incubation at 25°C, and the other API test was analyzed after at least 48 hours of incubation at 25°C. The results compared with other species are shown in Table 1 below.
[0146] Aerobic growth was checked in serum bottles by adding sodium thioglycolate (1 g / l) to R2A medium and replacing the upper air layer with nitrogen.
[0147] After 7 days of incubation at 25°C, the degradability of DNA, casein, starch, Tween 80 and carboxymethylcellulose was tested.
[0148] [Table 1]
[0149]
[0150]
[0151]
[0152] 1:EPI-7
[0153] 2:Modestobacter lapidis MON 3.1
[0154] 3:Sporichthya polymorpha DSM 43042
[0155] 4:Modestobacter marinus 42H12-1
[0156] +: positive, -: negative
[0157] The results showed that EPI-7 has the following culture and physiological characteristics:
[0158] (1) Aerobic;
[0159] (2) Heterotrophy;
[0160] (3) Oxidase negative and / or catalase negative
[0161] (4) Characteristics of Table 1;
[0162] (5) Growth was observed on R2A agar, but not on NA, ISP 2, and TSA;
[0163] (6) On R2A agar, growth was observed at 15°C to 35°C (optimum temperature: 25°C), but no growth was observed at 10°C or 40°C;
[0164] (7) Growth was observed at pH 5.0 to 6.5 and NaCl concentrations up to 10% (optimum pH 6.0, 0% NaCl);
[0165] (8) reduction of nitrate to nitrite; and
[0166] (9) Casein and starch are degraded, but DNA and carboxymethyl cellulose are not degraded.
[0167] Biochemical characteristics
[0168] DNA G+C content of EPI-7 was analyzed by HPLC. Specifically, the experimental methods and conditions used to analyze cellular fatty acid composition, G+C composition, and quinones are as follows.
[0169] First, the cell fatty acid composition of the isolated strain was analyzed according to Miller's method. About 40 mg of cultured cells were transferred to a tube, 1 ml of a solution prepared by adding 15% NaOH to 50% methanol was added, and the tube was heated at 100 ° C for 30 minutes and cooled at room temperature. 2 ml of methanol-HCl (a mixture of 325 ml 6.0 N HCl and 275 ml of methanol) was added to the tube, then heated at 80 ° C for 10 minutes, and then cooled rapidly. 1.25 ml of hexane / methyl tert-butyl ether (1: 1, v / v) was added thereto, and fully mixed for 10 minutes. After being placed at room temperature, when the reaction solution was divided into 2 layers, the lower layer was removed, 3 ml of diluted NaOH (10.8 g of sodium hydroxide / 900 ml of distilled water) was added, and after being fully mixed for 10 minutes, it was placed at room temperature. About 2 / 3 of the supernatant was transferred to a sample bottle (12×32 mm, Agilent Technologies) with a screw cap, covered with a lid, and then used as a sample. The sample was saponified, methylated and extracted according to the standard protocol of Sherlock MIS software. Fatty acids were analyzed using an Agilent Technologies 6890 gas chromatograph and a cross-linked methylsiloxane column (HP-1) of A30 m×0.320 mm×0.25 μm, and fatty acids were identified using the TSBA40 database (MIDI, version 4.5) of the MIS package. All experiments were repeated at least three times, and the results are shown in Table 2 below.
[0170] In addition, the G+C molar % was analyzed as follows. The DNA solution extracted from the strain was transferred to a microtube and centrifuged at 14000rpm for 5 minutes. Thereafter, 100μl of the supernatant was collected and transferred to a new tube, and DNA denaturation was performed at 100°C for 5 minutes, and then cooled. 10μl (0.1mg / mL) of P1 nuclease was added thereto, and it was reacted at 50°C for 3 hours. Alkaline phosphatase (10μl buffer and 5μl phosphatase) was added thereto, and then incubated at 37°C overnight. After centrifugation at 14000rpm for 5 minutes, the analysis was performed under the following conditions:
[0171] HPLC: YOUNG LIN YL9100 (YL9111 binary pump)
[0172] Detector: YOUNG LIN YL9120 UV / Vis detector
[0173] Chromatography data system: YOUNG LIN Autochro-3000
[0174] Analytical column: Waters Spherisorb 5um ODS2 4.6mm×250mm column
[0175] Eluent: 0.02M NH4H2PO4 (pH not adjusted)-acetonitrile (20:1, v / v)
[0176] Flow rate: 0.5mL / min
[0177] Detection wavelength: 270nm
[0178] Quinones were analyzed as follows: The strain was cultured in R2A medium at 25°C for 96 hours, and then only cells were collected and freeze-dried. The freeze-dried sample was extracted under the following conditions: a chloroform: methanol (2: 1) solution was added and shaken for 3 to 4 hours. The cells were filtered out using filter paper (Whatman No. 2) and the filtrate was concentrated. Thereafter, the concentrate was dissolved in 100 μl of chloroform: methanol (8.5: 1.5), and then centrifuged at 14000 rpm for 5 minutes to collect the supernatant, which was analyzed by HPLC. The HPLC conditions were as follows:
[0179] HPLC: YOUNG LIN YL9100 (YL9111 binary pump)
[0180] Detector: YOUNG LIN YL9120 UV / Vis detector
[0181] Chromatography data system: YOUNG LIN Autochro-3000
[0182] Analytical column: Waters Spherisorb 5um ODS2 4.6mm×150mm column
[0183] (column temperature 40℃)
[0184] Analysis solvent: methanol:isopropyl ether (4:1)
[0185] Flow rate: 1.0mL / min
[0186] Detection wavelength: 254mm.
[0187] Polar lipid analysis was performed after culturing the strain at 25°C for 96 hours in R2A medium. Polar lipids were first extracted from the strain according to the method described in Minnikin DE et al. (1984) (J Microbiol Methods 2, 233-241). Thereafter, polar lipids were identified by two-dimensional TLC (Komakata K et al., 1987, Methods Microbiol 19, 161-206).
[0188] [Table 2]
[0189]
[0190]
[0191] 1:EPI-7
[0192] 2:Modestobacter lapidis MON 3.1
[0193] 3:Sporichthya polymorpha DSM 43042
[0194] 4:Modestobacter marinus 42H12-1)
[0195] Summed Feature 3:C 16:1 ω6c and / or C 16:1 ω7c
[0196] Summed Feature 4: Anti-different BC 17:1 and / or different IC 17:1
[0197] Summed Feature 7:C 19:1 ω6c and / or ω7c and / or ring C 19:0
[0198] Summed Feature 8:C18:1 ω6c
[0199] Summed Feature 9: Iso-C 17:1 ω9c
[0200] The results showed that EPI-7 has the following biochemical characteristics:
[0201] (1) Tetrahydromethyl menaquinone (MK-9(H4)) with 9 units is the only isoprenoid quinone detected;
[0202] (2) the major polar lipids are phosphatidylethanolamine (PE), phosphatidylinositol (PI), three unidentified phospholipids (UPL), phosphatidylglycerol (PG), phosphatidylcholine (PC), two unidentified amino lipids (AL), and three UL;
[0203] (3) DNA G+C content is 68.9 mol%; and
[0204] (4) Fatty acid composition of Table 2.
[0205] Furthermore, its characteristics were compared with those of other microorganisms and are summarized in Table 3 below.
[0206] [Table 3]
[0207]
[0208]
[0209] As shown in Table 3, EPI-7 differs from the closest species in major biochemical characteristics, and these systematic and chemotaxonomic results of Example 2.1 demonstrate that EPI-7 is a new species.
[0210] In summary, it was demonstrated that EPI-7 isolated from human epidermal keratinocytes is a microorganism belonging to a new genus of the Ichthyosporaceae family and was named Epidermidibacterium gen. nov. according to the nomenclature of the Systematic Society.
[0211] Epidermidibacterium [E.pi.der.mi.di.bac.te'ri.um.NLn epidermis, -idis skin; L.neut.n. bacteria, (small rods or sticks); NLneut. (Epidermidibacterium small rods from the skin)].
[0212] Furthermore, as demonstrated in Example 2, the genus Epidermidibacterium has the following characteristics:
[0213] (1) Rod-shaped;
[0214] (2) non-motor;
[0215] (3) Gram-positive;
[0216] (4) No spores;
[0217] (5) oxidase negative and / or catalase negative;
[0218] (7) MK-9(H4) can be detected therefrom;
[0219] (8) The main polar lipids are PE, PI, PG, PC, and three ULs; and
[0220] (9) The DNA G+C content is 68.9 mol%.
[0221] Subsequently, the above results indicated that the Epidermidibacterium gen. nov. strain isolated from human epidermal keratinocytes was a species, which was named Epidermidibacterium keratini sp. nov according to the Systematic Society Nomenclature.
[0222] Epidermidibacterium keratini (ke.ra.ti'ni.NLgen.neut.n.keratini belongs to keratin).
[0223] Furthermore, as demonstrated in Example 2, in addition to the characteristics of the genus Epidermidibacterium, Epidermidibacterium keratini also has the following characteristics:
[0224] (1) The cell length is 0.5 μm to 0.3 μm and the diameter is 0.3 μm to 0.1 μm;
[0225] (2) The colonies are round, convex, and light yellow;
[0226] (3) Growth was observed on R2A (Reasoner's 2A) agar, but no growth was observed on nutrient agar (NA), yeast extract malt extract agar (ISP 2), and trypticase soy agar (TSA);
[0227] (4) On R2A agar, growth was observed at 15°C to 35°C (optimum temperature: 25°C), but no growth was observed at 10°C or 40°C;
[0228] (5) Growth was observed at pH 5.0 to 6.5 and NaCl concentrations up to 10% (optimum pH 6.0, 0% NaCl);
[0229] (6) Reduction of nitrate to nitrite;
[0230] (7) Casein and starch are degraded, but DNA and carboxymethyl cellulose are not degraded;
[0231] (8) The characteristics described in Tables 1 to 3 were observed;
[0232] (9) showing positive assimilation of one or more of the following: N-acetyl-D-glucosamine, N-acetyl-β-D-mannosamine, α-D-glucose, D-mannose, D-fructose, D-galactose, dextrin, D-fucose, inosine, lactamide, maltotriose, D-psicose, D-ribose, α-ketovaleric acid, D-fructose-6-PO4, L-serine, pectin, pyruvate, adenosine, thymidine, 2'-deoxyadenosine, 5'-adenosine monophosphate, p-hydroxyphenylacetic acid, methyl pyruvate, methyl D-lactate, L-lactic acid, citric acid, α-ketoglutaric acid, D-malic acid, L-malic acid, bromosuccinic acid, Tween 40, Tween 80, α-hydroxybutyric acid, β-hydroxy-D,L-butyric acid, α-ketobutyric acid, propionic acid, and acetic acid activity;
[0233] (10) Negative assimilation of one or more of the following: D-maltose, D-cellobiose, gentiobiose, sucrose, D-turanose, stachyose, D-raffinose, α-D-lactose, D-melibiose, β-hydroxy-methyl-D-glucoside, D-salicylic acid, N-acetyl-D-galactosamine, N-acetylneuraminic acid, D-sorbitol, D-mannitol, D-arabitol, inositol, glycerol, D-glucose-6-PO4, D-aspartic acid, D-serine, gelatin, glycyl-L- -Proline, L-Alanine, L-Arginine, L-Aspartic Acid, L-Glutamic Acid, L-Histidine, L-Pyroglutamic Acid, D-Galacturonic Acid, L-Galactone, D-Glucuronic Acid, D-Glucuronic Acid, Glucuronamide, Mucic Acid, Quinic Acid, D-Glucose, γ-Aminobutyric Acid, Formic Acid, α-Cyclodextrin, β-Cyclodextrin, Glycogen, Inulin, Mannan, N-Acetyl-D-Glucosamine, N-Acetyl-β-D-Mannosamine, Amygdalus Indole, L-Arabinose, Arbutin, L-Fucose, D-galactose, D-galacturonic acid, D-gluconic acid, lactulose, D-melezitose, α-methyl-D-galactoside, β-methyl-D-galactoside, 3-methylglucose, α-methyl-D-glucoside, β-methyl-D-glucoside, α-methyl-D-mannoside, palatinose, L-rhamnose, salicin, sedoheptalan, D-tagatose, D-trehalose, turanose, xylitol, D-xylose, acetic acid, γ-hydroxybutyric acid, p-hydroxyphenylacetic acid, D-methyl lactate, D-malic acid , L-malic acid, methyl pyruvate, monomethyl succinate, propionic acid, succinamic acid, N-acetyl-L-glutamate, L-alanineamine, D-alanine, L-alanylglycerol, glycyl-L-glutamate, L-pyroglutamate, putrescine, 2,3-butanediol, uridine, thymidine-5'-monophosphate, uridine-5'-monophosphate, D-fructose-6-phosphate, α-D-glucose-1-phosphate, D-glucose-6-phosphate, and DL-α-glycerophosphate;
[0234] (11) the presence of one or more activities selected from the group consisting of esterase (C4), esterase lipase (C8), leucine aryl amidase, cystine (crystine) aryl amidase, acid phosphatase, and naphthol-AS-BI-phosphohydrolase activity;
[0235] (12) the presence of weak alkaline phosphatase, valine arylamidase, or α-chymotrypsin activity;
[0236] (13) absence of one or more activities selected from the group consisting of lipase (C14), trypsin, α-galactosidase, β-glucuronidase, β-glucosidase, α-glucosidase, N-acetyl-β-glucosaminidase, α-mannosidase, and α-fucosidase activities; and
[0237] (14) The main fatty acids are C17:1ω8c, C16:0, iso-C15:0 or summed feature 3 (C 16:1 ω6c and / or C 16:1 ω7c).
[0238] The present inventors deposited the Epidermidibacterium keratini strain belonging to the genus Epidermidibacterium at the Korean Collection of Microorganisms (KCCM) on June 8, 2016 under the accession number KCCM11843P.
[0239] Example 3. Activity of strains
[0240] Analysis of skin-microbiome changes
[0241] To determine the effect of EPI-7 on changes in skin flora, changes in the skin microbiome of the subjects were analyzed.
[0242] Specifically, EPI-7 culture was applied to the skin of the subjects at intervals of 6 hours for a total of 72 hours, and skin samples were collected and analyzed. Samples were collected before culture treatment (epidermis A) and 72 hours after treatment (epidermis B). Samples were collected using sterile water and a scraper, and all procedures were performed on a clean bench. The samples collected from the skin were suspended in 0.85% NaCl, and the supernatant was centrifuged (17000rpm / m) to collect cells therefrom. The cells were washed once with sterile saline. Thereafter, DNA was extracted using FastDNA SPIN KIT (MP Biomedical, France). In order to amplify the 16S ribosomal DNA gene of the extracted DNA, 341F (sequence number 5) and 518R (sequence number 6) with a GC seal (sequence number 4) were used. For PCR reaction, 0.4mM dNTP, 0.5 unit Taq polymerase and 10μl TakaraPerfect Premix (Takara, Japan) containing 4mM Mg2+ were mixed with 1μl DNA template (20μg / mL) and 1μl 1.0μM forward primer and 1μl1.0μM reverse primer. Distilled water was added to the mixture to a total volume of 20μl. PCR reaction was carried out in C1000-Dual (Bio-Rad, the U.S.) by touchdown PCR method, in which amplification was implemented every two cycles while the temperature was reduced from 64°C to 59°C in the touchdown PCR method, and the PCR mixture was finally processed at 72°C for 8 minutes and stored at 4°C. Thereafter, the obtained PCR product was used for denaturation gradient gel electrophoresis (DGGE) analysis. In the DGGE analysis, the D-code system (Bio-rad, the U.S.) was used. A polyacrylamide gel with a concentration of 8% was used, and a 40% polyacrylamide double solution (29:1, 3.3% C) (Bio-Rad, USA) was used to prepare a gel with a vertical concentration gradient of 40-60%. At this time, 7M urea and 40% (w / v) formamide (Sigma, USA) were used as denaturants. The D-code system was filled with about 7L TAE buffer (20mM Tris, 10mM acetic acid, 0.5mM EDTA, pH8.0), and an equal amount of 2X loading dye (0.05% bromophenol blue, 0.05% xylene cyanol, 70% glycerol) and PCR products were mixed and electrophoresed at 50V for 800 minutes. The electrophoresed polyacrylamide gel was stained with Redsafe (Intron, South Korea) solution for 15 minutes, and the specific bands that appeared were analyzed. The results are shown in Figure 3 In addition, images of DGGE bands were quantified and analyzed using GelCompar2 (Bionumeric, Belgium) to generate histograms. For sequencing analysis, DGGE gel bands were sent to Macrogen and the results are shown in Figure 4 middle.
[0243] like Figure 3 and 4 As shown in , a decrease in the number of bands and an intense expression of specific bands were observed in epidermis B (after culture treatment) compared to epidermis A (before culture treatment). Increased expression of a band indicates an increase in population. Most of the DGGE bands with increased intensity represent Staphylococcus microorganisms belonging to the skin flora that coexist with the skin, which effectively strengthen the skin barrier and moisturize the skin.
[0244] These results suggest that EPI-7 affects skin barrier reinforcement and skin moisturizing by increasing microbiota.
[0245] 3.2. Analysis of skin wound healing, skin barrier enhancement and moisturizing activity
[0246] To analyze skin wound healing, skin barrier enhancement, and moisturizing activity, the expression levels of filaggrin, hyaluronan synthase (HAS3), claudin 1, claudin 4, αSMase, aquaporin 3 (AQP3), transglutaminase 1, and CerS3, which are factors associated with skin barrier enhancement and moisturizing activity, were examined by RT-PCR in a human keratinocyte cell line (HaCaT) according to EPI-7 treatment.
[0247] Specifically, HaCaT cells, which are human keratinocytes, were cultured in a DMEM medium (Dulbecco's modified Eagle's medium, Gibco 1210-0038) containing 10% fetal bovine serum, and the culture was carried out in an incubator at 37°C and 5% CO2. As a positive control group, the cultured cell line was treated with 1 mM retinol. As another positive control group, 20 ml of the cell culture solution was treated with a culture solution of Bifidobacterium animalis (UB) and Lactobacillus acidophilus (AB) at a concentration of 1%. In addition, the cells were treated with EPI-7 culture solution at a concentration of 0.1%, 0.5% or 1.0%.
[0248] After that, HaCaT cells were further incubated for 24 hours and recovered, and 1 ml of triazole (RNAiso, DAKARA, Japan) was added thereto to isolate RNA. In addition, for RT-PCR, RNA was quantified by using Nanodrop 2000 (Thermo, the United States), and reacted at 42 ° C for 55 minutes and at 70 ° C for 15 minutes to synthesize cDNA (reverse transcriptase mixed, ELPIS biotech, South Korea). RT-PCR was performed by using Step One Plus (Applied Biosystems, the United States), and SYBR Green supermix (Applied Biosystems, the United States) was added together with primers and cDNA. The polymerase was activated at 94 ° C for 5 minutes, and then 40 cycles of polymerization were performed at 95 ° C for 30 seconds, 54 ° C for 1 minute, and 72 ° C for 1 minute. Primers with sequence numbers 7 and 8 were used for filaggrin, primers with sequence numbers 9 and 10 were used for HAS3, primers with sequence numbers 11 and 12 were used for claudin 1, primers with sequence numbers 13 and 14 were used for claudin 4, primers with sequence numbers 15 and 16 were used for αSMase, primers with sequence numbers 17 and 18 were used for AQP3, primers with sequence numbers 19 and 20 were used for transglutaminase 1, primers with sequence numbers 21 and 22 were used for CerS3, and primers with sequence numbers 23 and 24 were used for β-actin.
[0249] Figure 5 It is a graph showing the comparison of the effect of EPI-7 on the expression of filaggrin in human keratinocytes and a positive control group.
[0250] Figure 6 It is a graph showing the comparison of the effects of EPI-7 on the expression of Claudin 4 in human keratinocytes and a positive control group.
[0251] Figure 7 is a graph showing the effects of different doses of EPI-7 on the expression of Claudin 4 in human keratinocytes.
[0252] Figure 8 is a graph showing comparison of the effects of EPI-7 on CerS3 expression in human keratinocytes and a positive control group.
[0253] Fig. 9 is a graph showing the effect of different doses of EPI-7 on CerS3 expression in human keratinocytes.
[0254] Fig.10 It is a graph showing the comparison of the effect of EPI-7 on the expression of αSMase in human keratinocytes and a positive control group.
[0255] Fig.11 is a graph showing the effect of different doses of EPI-7 on αSMase expression in human keratinocytes.
[0256] Fig.12 is a graph showing comparison of the effects of EPI-7 on HAS expression in human keratinocytes and a positive control group.
[0257] Fig.13 is a graph showing the effect of different doses of EPI-7 on HAS expression in human keratinocytes.
[0258] Fig.14 It is a graph showing the comparison of the effects of EPI-7 on transglutaminase 1 expression in human keratinocytes and a positive control group.
[0259] Fig.15 is a graph showing the effects of different doses of EPI-7 on the expression of Claudin 1 in human keratinocytes.
[0260] Fig.16 is a graph showing the effect of different doses of EPI-7 on the expression of aquaporin 3 in human keratinocytes.
[0261] like Figure 5 As shown in , EPI-7 was found to significantly increase the expression of filaggrin, a keratinocyte differentiation marker and a precursor protein of the natural wetting factor responsible for wetting the skin surface.
[0262] like Figure 6 , 7 and 15 , EPI-7 was found to significantly increase the expression of claudin 1 and 4, which are tight junction structures responsible for protecting internal organs from the external environment and maintaining the body’s homeostasis.
[0263] like Figure 8 and 11 As shown in , EPI-7 was found to significantly increase the expression of CerS3 and aSMase, which are essential enzymes for ceramide synthesis.
[0264] like Fig.12 and 13 As shown in , EPI-7 cultures were found to significantly increase the expression of the HAS3 gene, which is responsible for the synthesis of hyaluronic acid, an extracellular matrix component that maintains skin moisture, and EPI-7 showed higher efficacy than the positive control (retinol).
[0265] like Fig.14As shown in , EPI-7 was found to significantly increase the expression of transglutaminase 1, which plays a key role in the formation of cornified envelope.
[0266] like Fig.16 As shown in , EPI-7 was found to significantly increase the expression of AQP3, which plays a role in providing water to human skin, functions as a water channel to facilitate cell migration, and acts as a glycerol transporter to regulate keratinocyte proliferation and differentiation, thereby healing wounds.
[0267] Overall, it can be seen that EPI-7 enhances the flexibility and firmness of the skin, improves the water retention capacity of the skin, thereby exhibiting a skin moisturizing effect, strengthens the skin barrier function by more effectively controlling intercellular adhesion and the migration of aqueous solutes and water through the periplasmic space, and increases the proliferation, differentiation, and migration of keratinocytes to show a significant effect on wound healing.
[0268] Analysis of anti-inflammatory activity in the skin
[0269] To analyze the anti-inflammatory activity of EPI-7, HaCaT cells were treated with Staphylococcus aureus (S. aureus) as an inflammation inducer, and S. epidermidis and EPI-7 were co-cultured with human HaCaT cells, and then the mRNA expression levels of inflammatory factors were evaluated.
[0270] Specifically, HaCaT cells were cultured and seeded on 6-well plates. After 24 hours, a microwell was placed on top of the cell monolayer, and then live cells (SA: Staphylococcus aureus, SA_SE: Staphylococcus aureus + Staphylococcus epidermidis, SA_EPI-7: Staphylococcus aureus + EPI-7) were incubated at 1.0×10 14 The cells were further co-cultured for 24 hours, and then the cells and the culture medium were removed. RT-PCR was performed in the same manner as in Example 3.2, except that a combination of sequence numbers 25 and 26, a combination of sequence numbers 27 and 28, a combination of sequence numbers 29 and 30, and a combination of sequence numbers 31 and 32 were used as primers for TNF-α, IL-1a, TSLP, and DDIT3, respectively. The results are shown in Fig.17 middle.
[0271] Fig.17 This is a graph showing the effect of EPI-7 on inflammatory factors.
[0272] like Fig.17 As shown in , EPI-7 was found to significantly inhibit the expression of TNF-α, L-1a, TSLP, and DDIT3, which are skin inflammatory factors. This result indicates that EPI-7 and its culture medium can be used for diseases related to skin inflammation.
[0273] 3.4. Analysis of antipruritic activity in skin
[0274] In order to analyze the antipruritic activity of EPI-7, the mRNA expression levels of TSLP (thymic stromal lymphopoietin) and TARC (thymus and activation-regulated chemokine), which are itch factors, were evaluated. In detail, HaCaT cells were treated with polyinosinic acid: polycytidylic acid (Poly I: C), which is a synthetic ribonucleic acid that induces interferon production, and then cultured for 24 hours to stimulate HaCaT cells. The stimulated aged cells were treated with EPI-7 culture solution at a concentration of 0.1%, 0.5% or 1.0%, and further cultured for 24 hours. RT-PCR was performed in the same manner as in Example 3.3, except that a combination of sequence numbers 33 and 34 was used as TARC primers.
[0275] The results are shown in Fig.18 and 19 middle.
[0276] Fig.18 is a graph showing the effects of different doses of EPI-7 on TSLP expression in human keratinocytes.
[0277] Fig.19 is a graph showing the effects of different doses of EPI-7 on TARC expression in human keratinocytes.
[0278] like Fig.18 and 19 As shown in, EPI-7 was found to significantly reduce the expression of TSLP and TARC, which are itch factors. This result suggests that EPI-7 and its culture medium can be used for skin inflammation-related diseases and pruritus.
[0279] Cytotoxicity analysis
[0280] To examine the cytotoxicity of EPI-7, MTT assay was performed.
[0281] Specifically, HaCaT cells were prepared in the same manner as in Example 3.1, and 3×10 4The cells were distributed into a 96-well plate at a density of cells / well. After 24 hours, the medium without FBS was replaced. The EPI-7 culture medium was diluted with FBS-free medium at concentrations of 0.01%, 0.1%, 1%, 10% and 50% and used to treat the cells. After incubation for 24 hours, the medium was removed and 0.5μg / mL of MTT (Sigma-Aldrich, St. Louis, MO) solution was added to allow the cells to crystallize, and then incubated for another 4 hours. After removing the MTT reagent, the crystals were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO). The absorbance at 540nm was measured and compared with the untreated group to measure cell viability. The results are shown in Fig. 20 middle.
[0282] Fig. 20 is a graph showing the effect of EPI-7 on cell viability.
[0283] like Fig. 20 As shown in , EPI-7 was found to be non-cytotoxic even at high concentrations.
[0284] Sequence Listing <110> COSMAX CO., LTD. <120> New Ichthyosporaceae microorganisms and uses thereof <130> PX054386 <150> KR 10-2016-0080231 <151> 2016-06-27 <150> KR 10-2016-0155981 <151> 2016-11-22 <150> KR 10-2017-0076819 <151> 2017-06-16 <150> KR 10-2017-0076820 <151> 2017-06-16 <160> 34 <170> PatentIn version 3.5 <210> 1 <211> 1450 <212> DNA <213> Epidermidibacterium keratini <400> 1 caggacgaac gctggcggcg tgcttaacac atgcaagtcg agcgaagctc tcctcttcgg 60 aggagatgac ttagcggcga acgggtgagt aacacgtggg caacctgccc ttagctctgg 120 gataagcgat ggaaacgtcg tctaataccg gatacgacac ggaacggcat cattaccgtg 180 tggaaagaat ttcggctaag gatgggcccg cggcctatca gcttgttggt ggggtaatgg 240 cctaccaagg cttggacggg taaccggcct gagagggcga ccggtcacac tgggactgag 300 acacggccca gactctacg ggaggcagca gtggggaata ttgcacaatg ggcgaaagcc 360 tgatgcagcg acgccgcgtg agggatgacg gccttcgggt tgtaaacctc tttcagcagg 420 gacgaagcga aagtgacggt acctgcagaa gaagcgccgg ccaactacgt gccagcagcc 480 gcggtaatac gtagggcgca agcgttgtcc ggaattattg ggcgtaaaga gctcgtaggc 540 ggtttatcac gtcggctgtg aaatcccgag gcttaacctc gggcctgcag tcgatacggg 600 ttgactagag tgaagcaggg gagactggaa ttcctggtgt agcggtgaaa tgcgcagata 660 tcaggaggaa caccggtggc gaagggcgggt ctctgggctt taactgacgc tgaggagcga 720 aagcgtgggt agcgaacagg attagatacc ctggtagtcc acgccgtaaa cggtgggcgc 780 taggtgtggg gaccattcca cggtctccgt gccgcagcta acgcattaag cgccccgcct 840 ggggagtacg gccgcaaggc taaaactcaa aggaattgac gggggcccgc acaagcggcg 900 gagtatgttg cttaattcga tgcaacgcga agaaccttac caaggcttga catataccga 960 aaactcatag agatatgagg tccttttggg cggtatacag gtggtgcatg gttgtcgtca 1020 gctcgtgtcg tgagatgttg ggttaagtcc cgcaacgagc gcaaccctcg ttctatgttg 1080 ccagcacgta atggtgggga ctcataggag actgccgggg tcaactcgga ggaaggtggg 1140 gatgacgtca aatcatcatg ccccttatgt cttgggctgc aaacatacta caatggccgg 1200 tacaaagggc tgcgataccg taaggtggag cgaatcccaa aaagccggtc tcagttcgga 1260 ttggggtctg caactcgacc ccatgaagtc ggagtcgcta gtaatcgcag atcagcaacg 1320 ctgcggtgaa tacgttcccg ggccttgtac acaccgcccg tcaagtcatg aaagtcggta 1380 acacccgaag ccggtggcct aacctttttg gagggagccg tcgaaggtgg gactggcgat 1440 taggactaag 1450 <210> 2 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Bacterial Primers <400> 2 agagtttgat cmtggctcag 20 <210> 3 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Bacterial Primers <400> 3 tacggytacc ttgttacgac tt 22 <210> 4 <211> 40 <212> DNA <213> Artificial sequence <220> <223> GC seal for amplification of 16S ribosomal gene <400> 4 cgcccggggc gcgccccggg cggggcgggg gcacgggggg 40 <210> 5 <211> 17 <212> DNA <213> Artificial sequence <220> <223> Forward primer for amplification of 16S ribosomal gene <400> 5 cctacgggag gcagcag 17 <210> 6 <211> 17 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for amplification of 16S ribosomal gene <400> 6 attaccgcgg ctgctgg 17 <210> 7 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Forward primer for filaggrin <400> 7 agtgcactca gggggctcac a 21 <210> 8 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for filaggrin <400> 8 ccggcttggc cgtaatgtgt 20 <210> 9 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Forward primer for HAS3 <400> 9 cttaagggtt gcttgcttgc 20 <210> 10 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for HAS3 <400> 10 gttcgtggga gatgaaggaa 20 <210> 11 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Forward primer for claudin 1 <400> 11 gctctagaat tctcacacgt agtctttccc gct 33 <210> 12 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for claudin 1 <400> 12 gctctagaat tctcacacgt agtctttccc gct 33 <210> 13 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Forward primer for claudin 4 <400> 13 gctctagaat tccgagcgag tcatggccaa cgc 33 <210> 14 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for claudin 4 <400> 14 gctctagaat tctcacacgt agtctttccc gct 33 <210> 15 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> Forward primer for aSMase <400> 15 actttgataa ctgctcctct gac 23 <210> 16 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for aSMase <400> 16 ttcgtgtcca gcagagtacc 20 <210> 17 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Forward primer for AQP3 <400> 17 agacagcccc ttcaggattt 20 <210> 18 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for AQP3 <400> 18 tcccttgccc tgaatatctg 20 <210> 19 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Forward primer for TG1 <400> 19 ccccaagaga ctagcagtgg 20 <210> 20 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for TG1 <400> 20 agaccaggcc attcttgatg 20 <210> twenty one <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Forward primer for CerS3 <400> twenty one acattccaca aggcaaccat tg 22 <210> twenty two <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for CerS3 <400> twenty two ctcttgattc cgccgactcc 20 <210> twenty three <211> 20 <212> DNA <213> Artificial sequence <220> <223> Forward primer for β-actin <400> twenty three ggccatctct tgctcgaagt 20 <210> twenty four <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for β-actin <400> twenty four gacaccttca acaccccagc 20 <210> 25 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Forward primer for TNF-a <400> 25 cttctccttc ctgatcgtgg 20 <210> 26 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Reverse primer for TNF-a <400> 26 gctggttatc tctcagctcc a 21 <210> 27 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Forward primer for IL-1a <400> 27 tggctcattt tccctcaaaa gttg 24 <210> 28 <211> 25 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for IL-1a <400> 28 agaaatcgtg aaatccgaag tcaag 25 <210> 29 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Forward primer for TSLP <400> 29 gctatctggt gcccaggcta t 21 <210> 30 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Reverse primer for TSLP <400> 30 cgacgccaca atccttgtaa t 21 <210> 31 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Forward primer for DDIT3 <400> 31 tgcctttctc ttcggacact 20 <210> 32 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for DDIT3 <400> 32 tgtgacctct gctggttctg 20 <210> 33 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Forward primer for TARC <400> 33 cttctctgca gcacatcc 18 <210> 34 <211> 19 <212> DNA <213> Artificial sequence <220> <223> Reverse primer for TARC <400> 34 aagacctctc aaggctttg 19
Claims
1. Use of the Epidermidibacterium keratini strain deposited under the deposit number KCCM 11843P or the culture solution obtained by culturing the strain in the preparation of a cosmetic composition for strengthening the skin barrier, preventing or improving skin aging, moisturizing the skin, improving skin wounds, or preventing or improving skin inflammation.
2. Use of the Epidermidibacterium keratini strain deposited under the deposit number KCCM 11843P or the culture solution obtained by culturing the strain in the preparation of a cosmetic composition for preventing or improving any one of the group consisting of skin wounds, dermatitis, pruritus, eczematous skin diseases, urticaria, psoriasis, drug eruptions and acne.
3. Use of the Epidermidibacterium keratini strain deposited under the accession number KCCM 11843P or the culture solution obtained by culturing the strain in the preparation of a skin topical composition for preventing, improving or treating a skin disorder, wherein the skin disorder is one or more selected from the group consisting of skin wounds, dermatitis, pruritus, eczematous skin diseases, urticaria, psoriasis, drug eruptions and acne.
4. Use of the Epidermidibacterium keratini strain deposited under the deposit number KCCM 11843P or the culture fluid obtained by culturing the strain in the preparation of a pharmaceutical composition for preventing and treating skin diseases, wherein the skin diseases are one or more selected from the group consisting of skin wounds, dermatitis, pruritus, eczematous skin diseases, urticaria, psoriasis, drug eruptions and acne.
